Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Gains from Investment Securities (2018 - 2019)

Monopar Therapeutics (MNPR) has disclosed Gains from Investment Securities for 2 consecutive years, with $1.1 million as the latest value for Q4 2019.

  • Quarterly Gains from Investment Securities rose 1754.41% to $1.1 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2019, changed N/A year-over-year, with the annual reading at $104220.0 for FY2024, 121.89% up from the prior year.
  • Gains from Investment Securities hit $1.1 million in Q4 2019 for Monopar Therapeutics, up from -$65731.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.1 million in Q4 2019 to a low of -$65731.0 in Q4 2018.